NasdaqGM - Delayed Quote USD

Aura Biosciences, Inc. (AURA)

Compare
9.97 -0.10 (-0.99%)
At close: September 16 at 4:00 PM EDT
Loading Chart for AURA
DELL
  • Previous Close 10.07
  • Open 9.93
  • Bid 9.93 x 400
  • Ask 10.03 x 100
  • Day's Range 9.78 - 10.85
  • 52 Week Range 5.99 - 12.35
  • Volume 334,372
  • Avg. Volume 187,533
  • Market Cap (intraday) 494.573M
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) --
  • EPS (TTM) -1.79
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.00

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette?guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

www.aurabiosciences.com

88

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AURA

View More

Performance Overview: AURA

Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AURA
12.53%
S&P 500
18.10%

1-Year Return

AURA
5.95%
S&P 500
26.58%

3-Year Return

AURA
29.29%
S&P 500
22.32%

5-Year Return

AURA
29.29%
S&P 500
22.32%

Compare To: AURA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AURA

View More

Valuation Measures

Annual
As of 9/16/2024
  • Market Cap

    494.57M

  • Enterprise Value

    326.19M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.58

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.48%

  • Return on Equity (ttm)

    -45.09%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -80.69M

  • Diluted EPS (ttm)

    -1.79

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    187.42M

  • Total Debt/Equity (mrq)

    9.94%

  • Levered Free Cash Flow (ttm)

    -47.31M

Research Analysis: AURA

View More

Company Insights: AURA

Research Reports: AURA

View More

People Also Watch